Pharmaceutical Executive-10-17-2007

In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug.

New Web site allows users to create tribute dolls for breast cancer survivors. For every doll made, AZ will donate $1 to charity.

Swiss drug maker gears up to launch first in class Tekturna.

A federal district court ruled that FDA cannot fail to rule on a Sandoz's application for approval of omnitrope, a human growth hormone, just because it has no policy for generic biologics. Court watchers say the decision may help other generic biologics move forward in the approvals process.

Log on to CrazyMeds.org. Find out what patients say about your drugs, and what they think doctors and pharma don’t tell them.